60 Degrees Pharma announces IRB approval for Phase II study of tafenoquine in chronic babesiosis

60 DEGREES PHARMACEUTICALS, INC.

IRB-approved open-label Phase II study (NCT06656351) evaluating tafenoquine for chronic babesiosis.
Patient enrollment expected to begin in Q3 2025; participants must have >6 months functional impairment.
Company estimates cumulative addressable market of >400,000 patients through end of U.S. patent protection in 2035.
No approved treatment currently exists for chronic babesiosis.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.